Belgium’s position as one of Europe’s leading pharmaceutical markets is facing renewed scrutiny following concerns over delays in patient access to innovative medicines despite the country’s strong manufacturing and research base.

Recent discussions in Belgium’s parliamentary Health Committee highlighted growing debate around how reimbursement processes may be affecting the availability of new treatments. According to industry figures referenced during the hearing, only around half of innovative medicines authorised at European level between 2021 and 2024 had become available in Belgium by early 2026, with average access times extending beyond 18 months.

The discussion was prompted by wider questions around medicine pricing and reimbursement policy and included contributions from public health bodies, industry representatives and healthcare stakeholders.

Belgium remains a major pharmaceutical market within Europe, supported by significant levels of research activity, exports and private sector investment. The sector is also an important contributor to employment and national economic performance. However, stakeholders argued that delays in reimbursement decisions and uncertainty around pricing frameworks may influence future product launches and investment decisions.

Industry representatives pointed to a combination of factors affecting access timelines, including reimbursement evaluations, pricing expectations and procedural requirements. They also noted that some delays occur before formal submissions are made, while additional stages of negotiation can extend timelines further.

The debate has also focused attention on predictability within assessment processes and how governments balance affordability objectives with maintaining access to innovation.

Belgian authorities have introduced initiatives intended to accelerate access pathways for certain innovative medicines, with early responses from industry indicating cautious support while recognising operational and commercial challenges remain.

The issue extends beyond domestic healthcare policy. Belgium’s role within the European pharmaceutical landscape means changes in market access conditions may influence broader decisions relating to product launches, clinical research activity and long-term investment.

As European healthcare systems continue balancing cost pressures with innovation goals, the Belgian experience highlights the growing importance of creating transparent and efficient pathways that support both patient access and sector competitiveness.

Read more about developments shaping Europe’s pharmaceutical and life sciences sector.